Objective: This prospective study aimed to study the prognostic value of routine haematological and biochemical parameters in patients of acute hypertensive intracerebral hemorrhage (ICH) on fatality occurring during fi rst 30 days, and to estimate its case fatality rate, demographic and clinical correlates. Methods: One hundred and eleven consecutive patients with proved hypertensive ICH within 72 hours of symptom onset were studied. After clinical evaluation and neuroimaging, blood investigations including hemoglobin, total leukocyte count, platelet count, erythrocyte sedimentation rate, random blood sugar, urea, creatinine, sodium, potassium, serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), albumin estimations were performed. The patients were followed up for a maximum period of 30 days from the onset of stroke. Results: Logistic regression analysis demonstrated that a low Glasgow Coma Scale (GCS) score (Odd`s ratio (OR) 17.54, p=0.001); high serum bilirubin (OR=7.97, p=0.021), and low serum albumin (OR=13.31, p=0.001) correlated signifi cantly with death. Conclusions: Our study shows that low GCS, raised serum bilirubin, and low serum albumin are marker of poor outcome in ICH.

Background and Objective: This study aims to evaluate the safety and efficacy of edaravone, a novel free radical scavenger, in a group of Indian patients of acute ischemic stroke. Methods: Twenty two patients of acute ischemic stroke were given 30 mg of Edaravone twice daily for 14 days by infusion. The outcome assessment was by the Modified Rankin Scale (MRS) and Barthel Index (BI). MRS score ≤ 2 at 90 days was considered as a favorable outcome. Results: Fifteen patients (68%) had favorable outcome. The mean MRS score decreased from 4.01±0.92 at baseline to 1.86±1.07 at day 90 (p<0.005). The mean Barthel index increased from 40.00±30.11 at baseline to 75.62±22.86 at day 90 (p<0.005). The changes in the MRS and BI were observed from 7 days. None of the patients experienced any adverse effect. Conclusion: Edaravone treatment was safe and effective in providing early and sustained neurological improvement in patients with acute ischemic stroke.